- IDEXX Laboratories surpassed analyst expectations for both earnings per share (EPS) and revenue in its latest quarterly report.
- Growth was significantly driven by a 15% increase in its Companion Animal Group and the success of new platforms like IDEXX Cancer Dx™.
- Following its fourth consecutive quarter of beating estimates, the company has raised its financial outlook for the full year 2026.
IDEXX Laboratories (NASDAQ: IDXX) is a company that specializes in animal diagnostics and healthcare. It provides a wide range of products and services for veterinarians around the world. With a market capitalization of approximately $45.19 billion, it is a major company in the pet healthcare industry.
Before the market opened, IDEXX Laboratories announced its quarterly results, beating analyst expectations. The company reported an earnings per share (EPS) of $3.47. This figure was higher than the analyst consensus estimate of $3.41, showing strong profitability for the quarter.
The company also posted total revenue of $1.14 billion, which surpassed the estimated $1.12 billion. As highlighted by Zacks, this revenue represents a 14% increase from the $998.43 million reported in the same quarter of the previous year.
This growth was primarily driven by a 15% increase in its Companion Animal Group. As noted in a release by Business Wire, the company’s software, imaging, and its new IDEXX Cancer Dx™ platform are also gaining momentum and contributing to its success.
This report marks the fourth consecutive quarter that IDEXX Laboratories has exceeded estimates for both earnings and revenue. As a result of this sustained performance, the company has raised its financial outlook for the full year 2026, guiding for higher revenues and EPS.
